Cardiovascular complications of collagen vascular disease
Purchase on Springer.com
$39.95 / €34.95 / £29.95*
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.
Collagen vascular diseases commonly affect the heart; cardiovascular events are the major cause of mortality in people with these diseases. A striking feature of the cardiac involvement in individuals with systemic lupus erythematosus (SLE) and rheumatoid arthritis is aggressive and accelerated atherosclerosis; women with SLE in the 35-to 44-year-old age group are more than 50 times more likely to suffer myocardial infarction than are matched controls. Traditional risk factors contribute to the accelerated atherosclerosis, but cannot explain the extent of risk. It is possible that the inflammatory process, which is similar to the inflammatory process in atherosclerosis, pays a critical pathophysiologic role. It is critically important to identify the presence of traditional cardiovascular risk factors (eg, tobacco usage, hypertension, hypercholesterolemia, diabetes, homocysteinemia), and to modify these to secondary prevention targets. Cardiac valvular disease is common in individuals with SLE and rheumatoid arthritis; its presence should be anticipated and subacute bacterial endocarditis prophylaxis precautions initiated. Cardiac autonomic neuropathy and conduction disturbances are common in people with heart disease related to systemic sclerosis and human leukocyte antigen B27; these patients should be monitored carefully for evidence of dysrhythmias.
Collagen vascular diseases commonly affect the heart; cardiovascular events are the major cause of mortality in people with these diseases.
A striking feature of the cardiac involvement in individuals with systemic lupus erythematosus (SLE) and rheumatoid arthritis is aggressive and accelerated atherosclerosis; women with SLE in the 35-to 44-year-old age group are more than 50 times more likely to suffer myocardial infarction than are matched controls.
Traditional risk factors contribute to the accelerated atherosclerosis, but cannot explain the extent of risk. It is possible that the inflammatory process, which is similar to the inflammatory process in atherosclerosis, pays a critical pathophysiologic role.
It is critically important to identify the presence of traditional cardiovascular risk factors (eg, tobacco usage, hypertension, hypercholesterolemia, diabetes, homocysteinemia), and to modify these to secondary prevention targets.
Cardiac valvular disease is common in individuals with SLE and rheumatoid arthritis; its presence should be anticipated and subacute bacterial endocarditis prophylaxis precautions initiated.
Cardiac autonomic neuropathy and conduction disturbances are common in people with heart disease related to systemic sclerosis and human leukocyte antigen B27; these patients should be monitored carefully for evidence of dysrhythmias.
- Boumpas DT, Austin HA 3rd, Fessler BJ, et al.: Systemic lupus erythematosus: emerging concepts. Part 1: renal, neuropsychiatric, cardiovascular, pulmonary, and hematologic disease. Ann Int Med 1995, 122:940–950. An excellent review of more than 400 articles describing recent advances and controversies in the diagnosis and management of SLE with visceral involvement.
- Klemperer P, Pollack AD, Baehr G: Pathology of disseminated lupus erythematosus. Arch Pathol 1941, 32:569–631.
- Brigden W, Bywaters EGL, Lessof MH, Ross IP: The heart in systemic lupus erythematosus. Br Heart J 1960, 22:1–16.
- Hejtmancik MR, Wright JC, Quint R, Jennings FL: The cardiovascular manifestations of systemic lupus erythematosus. Am Heart J 1964, 68:119–130. CrossRef
- Bulkley BH, Roberts WC: The heart in systemic lupus erythematosus and the changes induced in it by corticosteroid therapy. A study of 36 necropsy patients. Am J Med 1975, 58:243–264. CrossRef
- Crozier IG, Li E, Milne MJ, Nicholls MG: Cardiac involvement in systemic lupus erythematosus detected by echocardiography. Am J Cardiol 1990, 65:1145–1148. This echocardiographic study demonstrates the frequency and characteristics of pericardial, valvular, and myocardial abnormalities detected in a series of 50 patients with SLE relative to matched controls. CrossRef
- Leung W-H, Wong K-L, Lau C-P, et al.: Doppler echocardiographic evaluation of left ventricular diastolic function in patients with systemic lupus erythematosus. Am Heart J 1990, 120:82–87. CrossRef
- Cervera R, Font J, Pare C, et al.: Cardiac disease in systemic lupus erythematosus: prospective study of 70 patients. Ann Rheumatic Dis 1992, 51:156–159.
- Nihoyannopoulos P, Gomez PM, Joshi J, et al.: Cardiac abnormalities in systemic lupus erythematosus. Association with raised anticardiolipin antibodies. Circulation 1990, 82:369–375.
- Louthrenoo W, Ruttanaumpawan P, Aramrattana A, Sukitawut W: Cardiovascular autonomic nervous system dysfunction in patients with rheumatoid arthritis and systemic lupus erythematosus. Q J Med 1999, 92:97–102.
- Galve E, Candell-Riera J, Pigrau C, et al.: Prevalence, morphologic types, and evolution of cardiac valvular disease in systemic lupus erythematosus. New Engl J Med 1988, 319:817–823. CrossRef
- Roldan CA, Shively BK, Lau CC, et al.: Systemic lupus erythematosus valve disease by transesophageal echocardiography and the role of antiphospholipid antibodies. J Am Coll Cardiol 1992, 20:1127–1134. CrossRef
- Straaton KV, Chatham WW, Reveille JD, et al.: Clinically significant valvular heart disease in systemic lupus erythematosus. Am J Med 1988, 85:645–650. CrossRef
- Khamashta MA, Cervera R, Asherson RA, et al.: Association of antibodies against phospholipids with heart valve disease in systemic lupus erythematosus. Lancet 1990, 335:1541–1544. CrossRef
- Leung WH, Wong KL, Lau C, et al.: Association between antiphospholipid antibodies and cardiac abnormalities in patients with systemic lupus erythematosus. Am J Med 1990, 89:411–419. CrossRef
- Vianna JL, Khamashta MA, Ordi-Ros J, et al.: Comparison of the primary and secondary antiphospholipid syndrome: a European Multicenter Study of 114 patients. Am J Med 1994, 96:3–9. CrossRef
- Gleason CB, Stoddard MF, Wagner SG, et al.: A comparison of cardiac valvular involvement in the primary antiphospholipid syndrome versus anticardiolipin-negative systemic lupus erythematosus. Am Heart J 1993, 125:1123–1129. CrossRef
- Zysset MK, Montgomery MT, Redding SW, Dell’Italia LJ: Systemic lupus erythematosus: a consideration for antimicrobial prophylaxis. Oral Surg Oral Med Oral Pathol 1987, 64:30–34. CrossRef
- Ward MM: Premature morbidity from cardiovascular and cerebrovascular diseases in women with systemic lupus erythematosus. Arthritis Rheum 1999, 42:338–346. CrossRef
- Manzi S, Meilahn EN, Rairie JE, et al.: Age-specific incidence rates of myocardial infarction and angina in women with systemic lupus erythematosus: comparison with the Framingham Study. Am J Epidemiol 1997, 145:408–415. These authors report the cardiovascular event rate and potential contributory factors in 498 women with SLE (3522 person-years) followed at the University of Pittsburgh Medical Center from 1980 to 1993. They stress the impact of accelerated atherosclerosis and the need for aggressive management of risk factors.
- Manzi S, Selzer F, Sutton-Tyrell K, et al.: Prevalence and risk factors of carotid plaque in women with systemic lupus erythematosus. Arthritis Rheum 1999, 42:51–60. CrossRef
- Roman MJ, Salmon JE, Sobel R, et al.: Prevalence and relation to risk factors of carotid atherosclerosis and left ventricular hypertrophy in systemic lupus erythematosus and antiphospholipid antibody syndrome. Am J Cardiol 2001, 87:663–666. CrossRef
- Rahman P, Aguero S, Gladman DD, et al.: Vascular events in hypertensive patients with systemic lupus erythematosus. Lupus 2000, 9:672–675. CrossRef
- Svenungsson E, Jensen-Urstad K, Heimbürger M, et al.: Risk factors for cardiovascular disease in systemic lupus erythematosus. Circulation 2001, 104:1887–1893.
- Kitas G, Banks MJ, Bacon PA: Cardiac involvement in rheumatoid disease. Clin Med 2001, 1:18–21. This is a detailed review of the pericardial disease, valvulitis, myocardial involvement, and coronary artery disease that accompany RA. The authors stress that cardiovascular disease, particularly coronary artery disease, occurs early and causes almost 50% of all RA deaths. Valvular and myocardial involvement is usually clinically silent.
- Manzi S, Wasko MCM: Inflammation-mediated rheumatic diseases and atherosclerosis. Ann Rheum Dis 2000, 59:321–325. CrossRef
- Sokolof L: The heart in rheumatoid arthritis. Am Heart J 1953, 45:635–643. CrossRef
- Cathcart ES, Spodick DH: Rheumatoid heart disease. N Engl J Med 1962, 266:959–964. CrossRef
- Bonfiglio T, Atwater EC: Heart disease in patients with seropositive rheumatoid arthritis; a controlled autopsy study. Arch Intern Med 1969, 124:714–719. CrossRef
- Bacon PA, Gibson DG: Cardiac involvement in rheumatoid arthritis. An echocardiographic study. Ann Rheum Dis 1974, 33:20–24.
- MacDonald WJ Jr, Crawford MH, Klippel JH, et al.: Echocardiographic assessment of cardiac structure and function in rheumatoid arthritis. Am J Med 1977, 63:890–896. CrossRef
- Escalante A, Kaufman R, Fransisco P, et al.: Cardiac compression in RA. Semin Arthritis Rheum 1990, 20:148–163. CrossRef
- Slack D, Waller B: Acute congestive heart failure due to the arteritis of rheumatoid arthritis. Early diagnosis by endomyocardial biopsy. Angiology 1986, 6:477–481.
- Corrao S, Salli L, Arnone S, et al.: Echodoppler abnormalities in patients with rheumatoid arthritis without clinically evident cardiovascular disease. Eur J Clin Invest 1996, 26:293–297. CrossRef
- Banks MJ, Flint EJ, Bacon PA, Kitas GD: Rheumatoid arthritis is an independent risk factor for ischaemic heart disease. Arthritis Rheum 2000, 43:S385.
- Pasceri V, Yeh ETH: A tale of two diseases. Atherosclerosis and rheumatoid arthritis. Circulation 1999, 100:2124–2126. This editorial summarizes and compares data currently available describing the inflammatory and immunologic responses observed in atherosclerosis, unstable angina, and RA, pointing out striking similarities in macrophage, T cell, B cell, and mast cell activation as well as cytokine, adhesion molecule, and endothelin concentrations. The authors speculate that a common pathophysiologic process exists.
- Kitas G, Banks MJ, Bacon PA: Accelerated atherosclerosis as a cause of cardiovascular death in rheumatoid arthritis. Pathogenesis 1998, 1:73–83.
- Del Rincon ID, Williams K, Stern MP, et al.: High incidence of cardiovascular events in a rheumatoid arthritis cohort not explained by traditional cardiac risk factors. Arthritis Rheum 2001, 44:2737–2745. The authors present data from the San Antonio Heart Study indicating a threefold greater incidence of cardiovascular disease in RA, and demonstrate that the increased risk is independent of traditional risk factors, suggesting that increased inflammatory activity or oxidative stress may be operative. CrossRef
- Asanuma Y, Kawai S, Aoshima H, et al.: Serum lipoprotein(a) and apolipoprotein(a) phenotypes in patients with rheumatoid arthritis. Arthritis Rheum 1999, 42:443–447. CrossRef
- Hernanz A, Plaza A, Martín-Mola E, De Migues E: Increased plasma levels of homocysteine and other thiol compounds in rheumatoid arthritis women. Clin Biochem 1999, 1:65–70. CrossRef
- Generini S, Fiori G, Moggi-Pignone A, et al.: Systemic sclerosis: a clinical overview. Advan Exper Med Biol 1999, 455:75–83. This chapter reviews the multiorgan system involvement of SSc, and presents a concise summary of scleroderma heart disease.
- Deswal A, Follansbee WP: Cardiac involvement in scleroderma. Rheum Dis Clin N Am 1996, 22:841–860. CrossRef
- Follansbee WP, Zerbe TR, Medsger TA Jr: Cardiac and skeletal muscle disease in systemic sclerosis (scleroderma): a high risk association. Am Heart J 1993, 125:194–203. CrossRef
- James TN: De subitaneis mortibus: VIII. Coronary arteries and conduction system in scleroderma heart disease. Circulation 1974, 50:844–856.
- D’Angelo WA, Fries JF, Masi AT, Shulman LE: Pathologic observations in systemic sclerosis (scleroderma): a study of 58 autopsy cases and 58 matched controls. Am J Med 1969, 46:428–440. CrossRef
- Follansbee WP, Miller TR, Curtiss EI, et al.: A controlled clinicopathologic study of myocardial fibrosis in systemic sclerosis (scleroderma). J Rheumatol 1990, 17:656–662.
- Bulkley BH, Ridolfi RL, Salyer WR, Hutchins GM: Myocardial lesions of progressive systemic sclerosis: a cause of cardiac dysfunction. Circulation 1976, 53:483–490.
- Follansbee WP, Curtiss EI, Medsger TA Jr, et al.: Physiologic abnormalities of cardiac function in progressive systemic sclerosis with diffuse scleroderma. N Engl J Med 1984, 310:142–148. CrossRef
- Alexander EL, Firestein GS, Weiss JL, et al.: Reversible cold-induced abnormalities in myocardial perfusion and function in systemic sclerosis. Ann Intern Med 1986, 105:661–672.
- Kahan A, Devaux JY, Amor B, et al.: The effect of captopril on thallium 201 myocardial perfusion in systemic sclerosis. Clin Pharmacol Ther 1990, 47:483–489. CrossRef
- Kahan A, Devaux JY, Amor B, et al.: Nifedipine and thallium-201 myocardial perfusion in progressive systemic sclerosis. N Engl J Med 1986, 314:1397–1402. CrossRef
- Gustafsson R, Mannting F, Kazzam E, et al.: Coldinduced abnormalities in myocardial perfusion and function in systemic sclerosis. Lancet 1989, 2:475–476. CrossRef
- Steen VD, Follansbee WP, Conte CG, Medsger TA Jr: Thallium perfusion defects predict subsequent cardiac dysfunction in patients with systemic sclerosis. Arthritis Rheum 1996, 39:677–681. CrossRef
- Follansbee WP, Curtiss EI, Rahko PS, et al.: The electrocardiogram in systemic sclerosis (scleroderma). Study of 102 consecutive cases with functional correlations and review of the literature. Am J Med 1985, 79:183–192. CrossRef
- Di Bello V, Ferri C, Giorgi D, et al.: Ultrasonic videodensitometric analysis in scleroderma heart disease. Coron Artery Dis 1999, 10:103–110.
- Ferri C, Emdin M, Giuggioli D, et al.: Autonomic dysfunction in systemic sclerosis: time and frequency domain 24 hour heart rate variability analysis. Br J Rheum 1997, 36:669–676. CrossRef
- Pignone A, Matucci-Cerini M, Becucci A, et al.: Patterns of late ventricular late potentials in systemic sclerosis: a noninvasive method in the study of cardiac involvement. Ann Ital Med Int 1994, 9:141–155.
- Rosada M, Cozzi F, Bullo A, et al.: Prevalence of ventricular late potentials in systemic sclerosis and analysis of clinical and 24 hour electrocardiography associations. Reumatismo 1997, 49(suppl_3):221.
- Morelli S, Sgreccia A, De Marzio P, et al.: Noninvasive assessment of myocardial involvement in patients with systemic sclerosis: role of signal averaged electrocardiography. J Rheumatol 1997, 24:2358–2363.
- Ho M, Veale D, Eastmond C, et al., for the East of Scotland Systemic Sclerosis Study Group: Macrovascular disease and systemic sclerosis. Ann Rheum Dis 2000, 59:39–43. CrossRef
- Bergfeldt L: HLA-B27-associated cardiac disease. Ann Intern Med 1997, 127:621–629. The author summarizes available information about cardiac disease in relation to the immunogenetic marker HLA-B27 and its associated inflammatory disorders. He stresses that the heart and joints are both of major importance as targets for the HLA-B27-associated disease process, and that HLAB27 -related cardiac lesions may be found in the absence of other rheumatologic manifestations. He further suggests a genetically linked cardiac syndrome: the combination of conduction system abnormalities and aortic regurgitation.
- Bergfeldt L, Edhag O, Vallin H: Cardiac conduction disturbances, an underestimated manifestation in ankylosing spondylitis. A 25-year follow-up study of 68 patients. Acta Med Scand 1982, 212:217–223. CrossRef
- Bergfeldt L, Vallin H, Edhag O: Complete heart block in HLA B27 associated disease. Electrophysiological and clinical characteristics. Br Heart J 1984, 51:184–188.
- Cruickshank B: Pathology of ankylosing spondylitis. Clin Orthop 1971, 74:43–58.
- Brewerton DA, Gibson DG, Goddard DH, et al.: The myocardium in ankylosing spondylitis. A clinical, echocardiographic, and histopathological study. Lancet 1987, 1:995–998. CrossRef
- Gould BA, Turner J, Keeling DH, et al.: Myocardial dysfunction in ankylosing spondylitis. Ann Rheum Dis 1992, 51:227–232. CrossRef
- Hassel D, Heinsimer J, Califf RM, et al.: Complete heart block in Reiter’s syndrome. Am J Cardiol 1984, 53:967–968. CrossRef
- Hallegua DS, Wallace DJ: How accelerated atherosclerosis in SLE has changed our management of the disorder. Lupus 2000, 9:228–231. This article describes the accelerated atherosclerotic process and the importance of monitoring and treating the known risks factors, as well as the possible roles of homocysteine and antiphospholipid antibodies. The authors suggest a treatment algorithm to reduce the incidence of coronary artery disease in patients with SLE. CrossRef
- Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults: Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA 2001, 285:2486–2497. These are the most recent guidelines designed to identify risk factors for cardiovascular disease, allow risk assessment of individual patients based upon Framingham data, and provide treatment targets based upon overall risk. CrossRef
- Thiagarajan P: Atherosclerosis, autoimmunity, and systemic lupus erythematosus. Circulation 2001, 104:1876–1877. In this editorial, the author discusses the pathophysiologic processes by which inflammation produces vascular injury and atherosclerosis.
- Dzielak DJ: AIDS, lupus, rheumatoid arthritis—hypertension? Hypertension 1990, 15:95–96.
- Strand V: New therapies for systemic lupus erythematosus. Rheumatic Dis Clin N Amer 2000, 26:389–406. CrossRef
- Callen JP: New and emerging therapies for collagenvascular diseases. Dermatol Clin 2000, 18:139–146. CrossRef
- Julkunen H: Hormone replacement therapy in women with rheumatic diseases. Scand J Rheumatol 2000, 29:146–153. CrossRef
- Mosca L, Collins P, Herrington DM, et al.: Hormone replacement therapy and cardiovascular disease. A statement for healthcare professionals from the American Heart Association. Circulation 2001:104:499–503.
- Mukherjee D, Nissen SE, Topol EJ: Risk of cardiovascular events associated with selective COX-2 inhibitors. JAMA 2001, 286:954–959. CrossRef
- Konstam MA, Weir MR, Reicin A, et al.: Cardiovascular thrombotic events in controlled, clinical trials of rofecoxib. Circulation 2001, 104:r15-r23.
- Garcia Rodriguez LA, Varas C, Patrono C: Differential effects of aspirin and non-aspirin nonsteroidal antiinflammatory drugs in the primary prevention of myocardial infarction in postmenopausal women. Epidemiology 2000, 11:382–387. CrossRef
- Moro H, Hayashi J, Ohzeki H, et al.: Surgical management of cardiovascular lesions caused by systemic inflammatory diseases. Thorac Cardiovasc Surg 1999, 47:106–110. CrossRef
- Cardiovascular complications of collagen vascular disease
Current Treatment Options in Cardiovascular Medicine
Volume 4, Issue 2 , pp 151-159
- Cover Date
- Print ISSN
- Online ISSN
- Current Medicine Group
- Additional Links